Why the study?
Do simulated mexiletine and ranolazine reduce action potential duration prolongation in in silico LQT3 hiPSC-CM models?
Population
In silico human induced pluripotent stem cell-derived cardiomyocyte models for control and LQT3 caused by…
Comparison
Simulated mexiletine and ranolazine multichannel… vs Control hiPSC-CM models and asymptomatic LQT3…
Design
Preclinical
Authors
Loading...
In silico modeling may clarify ionic drivers of hiPSC-CM variability in LQTS; leaves open experimental validation and clinical translation.
Do simulated mexiletine and ranolazine reduce action potential duration prolongation in in silico LQT3 hiPSC-CM models?
In silico modeling of LQT3 hiPSC-CMs successfully recapitulates phenotypic variability and demonstrates that mexiletine is more effective than ranolazine at stopping spontaneous action potentials.
Paci et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: